/PRNewswire/ Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today its decision not to continue the.
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated.
Janssen Pharmaceuticals : Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
05/26/2021 | 08:49am EDT
Send by mail :
Message : +1 800-526-7736 Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis Further analysis from the Phase 3 ANDROMEDA study presented at the 2021 ASCO Annual Meeting also show doubling rates of organ response with no new safety signals for the first FDA-approved treatment in a rare blood cell disorder RARITAN, N.J., May 26, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for
/PRNewswire/ Learn about light chain (AL) amyloidosis and a new treatment option for this rare and serious blood cell disorder. Experience the interactive.